The Analytical Chemistry of Cannabis
Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations
Emerging Issues in Analytical Chemistry Series

1. The Botany of Cannabis sativa L.
2. Biosynthesis and Pharmacology of Phytocannabinoids and Related Chemical Constituents
3. Medical Cannabis Formulations
4. Analytical Methods in Formulation Development and Manufacturing
5. Quality Control and Stability Assessment
6. The Roles of Research and Regulation
7. The Future of Cannabinoid Therapeutics

Analytical chemists, pharmacologists, medical doctors, clinical trials specialists, public health officials, international food and drug monitoring agencies, forensics specialists, law enforcement; Advanced undergraduate and graduate level courses in pharmacy, pharmacology, experimental therapeutics, analytical chemistry, and forensics

Brian F. Thomas earned his doctoral degree in 1992 from the Medical College of Virginia/Virginia Commonwealth University, USA. He then joined Research Triangle Institute and assumed the role of Principal Investigator on National Institute on Drug Abuse (NIDA) research contracts titled “Purity Specifications, Storage and Distribution for Medications Development,” “Preparation and Distribution of Research Drug Products,” and “Production, Analysis and Distribution of Cannabis, Marijuana Cigarettes and Related Materials.” Serving in these roles, he coordinated the preparation and analysis of research drugs and substance abuse treatment medications at RTI for over 28 years. In addition to contract research, Dr. Thomas served as Principal Investigator on several NIDA R01 grant-funded research awards involving the characterization of cannabinoid ligand-receptor interactions and their relationship to in vivo pharmacological effects.

In 2019, he joined Canopy Growth Corporation as Senior Director, Analytical Chemistry, Discovery Sciences, and Pharmaceutics, where he had management oversight of drug substance and product testing to support preclinical and clinical studies of cannabinoids in accordance with regulatory guidance. He also directed the integration of medicinal chemistry and in vitro pharmacological screening approaches to support development of consumer products and drive clinical drug discovery and therapeutic product development and commercialization efforts. He was subsequently recruited by The Cronos Group to serve as the Director of Analytical Sciences, with management oversight of scientists at production and research and development facilities in the United States, Canada, and Israel. He also engaged with the US Hemp Roundtable and other trade and scientific organizations to provide critical input to regulations and regulatory oversight by state, federal, and international regulatory authorities. He is currently providing pharmaceutical consulting s